<p>Fennec Pharmaceuticals（纳斯达克股票代码：FENC - 获取免费报告）的股票在周二的一份报告中被 Wedbush 分析师重申为&#34;表现优异&#34;，据 RTT News 报道。他们目前对该股的目标价格为 14.00 美元，低于之前的 16.00 美元。Wedbush 的价格目标表明，该股有望上涨 139.32%，相对于上一个交易日的收盘价。</p>
<p>获取 <strong>Fennec Pharmaceuticals</strong> 的提醒：</p>
<p>FENC 已成为其他研究报告的主题。HC Wainwright 将 Fennec Pharmaceuticals 的目标股价从 18.00 美元降至 15.00 美元，并在 5 月 15 日星期三的一份报告中为该公司设定了&#34;买入&#34;评级。Craig Hallum 将 Fennec Pharmaceuticals 的目标股价从 20.00 美元降至 17.00 美元，并在 5 月 15 日星期三的一份研究报告中为该公司设定了&#34;买入&#34;评级。</p>
<p><strong>查看我们关于 FENC 的最新股票报告</strong></p>
<h2>Fennec Pharmaceuticals 股价下跌 6.4%</h2>
<p>FENC 股票在周二的午盘交易中下跌了 0.40 美元，报 5.85 美元。该股交易量为 192,799 股，相比其平均交易量 122,792 股有所增加。该股的 50 天简单移动平均线为 6.37 美元，200 天简单移动平均线为 8.35 美元。Fennec Pharmaceuticals 的 12 个月最低价为 5.30 美元，最高价为 11.92 美元。该公司的速动比率为 6.72，流动比率为 6.93，负债权益比为 9.86。该公司的市值为 1.5987 亿美元，市盈率为 195.00，β系数为 0.29。</p>
<p>Fennec Pharmaceuticals（纳斯达克股票代码：FENC - 获取免费报告）于 5 月 14 日星期二发布了季度财报。该公司报告称，该季度每股收益（EPS）为 0.41 美元，低于市场预期的 0.49 美元。该季度，公司营收为 2538 万美元，超过分析师预期的 1046 万美元。Fennec Pharmaceuticals 的净资产回报率为-39.41%，净利润率为 6.33%。与去年同期相比，该公司当季每股收益为（0.23）美元。卖方分析师预计，Fennec Pharmaceuticals 今年财年的每股收益将为 0.36 美元。</p>
<h2>对 Fennec Pharmaceuticals 进行投资的对冲基金观点</h2>
<p>一些大型投资者最近调整了他们对该股的持股。Tower Research Capital LLC TRC 在第四季度增加了对 Fennec Pharmaceuticals 的持股比例 107.3%。Tower Research Capital LLC TRC 现在拥有该公司的 3,048 股股票，价值 34,000 美元，较上一季度增加了 1,578 股。Acadian Asset Management LLC 在第二季度收购了 Fennec Pharmaceuticals 的新头寸，价值约 49,000 美元。Jump Financial LLC 在第四季度收购了 Fennec Pharmaceuticals 的新头寸，价值约 158,000 美元。Rhumbline Advisers 在第二季度将其对 Fennec Pharmaceuticals 的持股比例增加了 44.7%。Rhumbline Advisers 现在拥有该公司的 29,110 股股票，价值 178,000 美元，较上一季度增加了 8,987 股。最后，BNP Paribas Financial Markets 在第一季度将其对 Fennec Pharmaceuticals 的持股比例增加了 67.7%。BNP Paribas Financial Markets 现在拥有该公司的 32,769 股股票，价值 364,000 美元，较上一季度增加了 13,223 股。机构投资者拥有该公司 55.51% 的股份。</p>
<h2>Fennec Pharmaceuticals 公司简介（获取免费报告）</h2>
<p>Fennec Pharmaceuticals Inc 是一家生物制药公司，致力于开发用于治疗美国癌症的产品候选药物。其主要产品候选药物是硫代硫酸钠，已完成用于预防儿童顺铂诱导性听力损失或耳毒性的 III 期临床试验。</p>
<h2>精选故事</h2>
<ul>
<li>我们喜欢的五只股票，比 Fennec Pharmaceuticals 更好</li>
<li>什么是股息？购买最佳股息股票</li>
<li>在市场抓住第二春之前购买 Holdings 股票</li>
<li>如何投资科技股，以及考虑的顶级科技股</li>
<li>3 只有潜力的股票可能成为多倍赚家</li>
<li>什么是债券市场假日？如何投资和交易</li>
<li>CEO 交换：星巴克因从 Chipotle 聘请新 CEO 而大涨 22%</li>
</ul>
<p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 在亿万富翁买光之前，先确保这支&#34;AI 燃料&#34;股票（来自市场背后）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTQ4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTQ4"/></p>
<h2>现在是否值得投资 1000 美元购买 Fennec Pharmaceuticals？</h2>
<p>在考虑 Fennec Pharmaceuticals 之前，您会想听听这个。</p>
<p>MarketBeat 追踪华尔街顶级和表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 Fennec Pharmaceuticals 不在名单上。</p>
<p>尽管 Fennec Pharmaceuticals 目前在分析师中有&#34;买入&#34;评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

FENC

<p>Wedbush 重申对 Fennec Pharmaceuticals 的 “跑赢市场” 评级，并设定目标价格为$14.00。该股票的潜在上涨空间为 139.32%，相较前一交易日收盘价。Fennec Pharmaceuticals 是一家生物制药公司，致力于开发治疗癌症的产品候选药物</p>

<p>Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report)'s stock had its &#34;outperform&#34; rating reaffirmed by analysts at Wedbush in a note issued to investors on Tuesday, RTT News reports. They presently have a $14.00 target price on the stock, down from their prior target price of $16.00. Wedbush's price objective would suggest a potential upside of 139.32% from the stock's previous close.</p>
<div class="lb-trans"><p>Fennec Pharmaceuticals（纳斯达克股票代码：FENC - 获取免费报告）的股票在周二的一份报告中被 Wedbush 分析师重申为&#34;表现优异&#34;，据 RTT News 报道。他们目前对该股的目标价格为 14.00 美元，低于之前的 16.00 美元。Wedbush 的价格目标表明，该股有望上涨 139.32%，相对于上一个交易日的收盘价。</p>
</div><p>Get <strong>Fennec Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Fennec Pharmaceuticals</strong> 的提醒：</p>
</div><p>FENC has been the subject of a number of other research reports. HC Wainwright reduced their price target on Fennec Pharmaceuticals from $18.00 to $15.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, May 15th. Craig Hallum reduced their target price on Fennec Pharmaceuticals from $20.00 to $17.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, May 15th.</p>
<div class="lb-trans"><p>FENC 已成为其他研究报告的主题。HC Wainwright 将 Fennec Pharmaceuticals 的目标股价从 18.00 美元降至 15.00 美元，并在 5 月 15 日星期三的一份报告中为该公司设定了&#34;买入&#34;评级。Craig Hallum 将 Fennec Pharmaceuticals 的目标股价从 20.00 美元降至 17.00 美元，并在 5 月 15 日星期三的一份研究报告中为该公司设定了&#34;买入&#34;评级。</p>
</div><p><strong>View Our Latest Stock Report on FENC</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 FENC 的最新股票报告</strong></p>
</div><h2>Fennec Pharmaceuticals Stock Down 6.4 %</h2>
<div class="lb-trans"><h2>Fennec Pharmaceuticals 股价下跌 6.4%</h2>
</div><p>Shares of FENC traded down $0.40 during mid-day trading on Tuesday, reaching $5.85. 192,799 shares of the stock traded hands, compared to its average volume of 122,792. The stock has a fifty day simple moving average of $6.37 and a 200 day simple moving average of $8.35. Fennec Pharmaceuticals has a 12-month low of $5.30 and a 12-month high of $11.92. The company has a quick ratio of 6.72, a current ratio of 6.93 and a debt-to-equity ratio of 9.86. The firm has a market cap of $159.87 million, a price-to-earnings ratio of 195.00 and a beta of 0.29.</p>
<div class="lb-trans"><p>FENC 股票在周二的午盘交易中下跌了 0.40 美元，报 5.85 美元。该股交易量为 192,799 股，相比其平均交易量 122,792 股有所增加。该股的 50 天简单移动平均线为 6.37 美元，200 天简单移动平均线为 8.35 美元。Fennec Pharmaceuticals 的 12 个月最低价为 5.30 美元，最高价为 11.92 美元。该公司的速动比率为 6.72，流动比率为 6.93，负债权益比为 9.86。该公司的市值为 1.5987 亿美元，市盈率为 195.00，β系数为 0.29。</p>
</div><p>Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report) last released its quarterly earnings results on Tuesday, May 14th. The company reported $0.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by ($0.08). The firm had revenue of $25.38 million for the quarter, compared to analysts' expectations of $10.46 million. Fennec Pharmaceuticals had a negative return on equity of 39.41% and a net margin of 6.33%. During the same period last year, the firm earned ($0.23) EPS. Sell-side analysts expect that Fennec Pharmaceuticals will post 0.36 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Fennec Pharmaceuticals（纳斯达克股票代码：FENC - 获取免费报告）于 5 月 14 日星期二发布了季度财报。该公司报告称，该季度每股收益（EPS）为 0.41 美元，低于市场预期的 0.49 美元。该季度，公司营收为 2538 万美元，超过分析师预期的 1046 万美元。Fennec Pharmaceuticals 的净资产回报率为-39.41%，净利润率为 6.33%。与去年同期相比，该公司当季每股收益为（0.23）美元。卖方分析师预计，Fennec Pharmaceuticals 今年财年的每股收益将为 0.36 美元。</p>
</div><h2>Hedge Funds Weigh In On Fennec Pharmaceuticals</h2>
<div class="lb-trans"><h2>对 Fennec Pharmaceuticals 进行投资的对冲基金观点</h2>
</div><p>Several large investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC lifted its stake in Fennec Pharmaceuticals by 107.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,048 shares of the company's stock worth $34,000 after purchasing an additional 1,578 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of Fennec Pharmaceuticals in the 2nd quarter valued at about $49,000. Jump Financial LLC acquired a new position in shares of Fennec Pharmaceuticals in the 4th quarter valued at about $158,000. Rhumbline Advisers grew its position in shares of Fennec Pharmaceuticals by 44.7% during the 2nd quarter. Rhumbline Advisers now owns 29,110 shares of the company's stock valued at $178,000 after buying an additional 8,987 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its stake in Fennec Pharmaceuticals by 67.7% during the first quarter. BNP Paribas Financial Markets now owns 32,769 shares of the company's stock worth $364,000 after acquiring an additional 13,223 shares during the period. Institutional investors own 55.51% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投资者最近调整了他们对该股的持股。Tower Research Capital LLC TRC 在第四季度增加了对 Fennec Pharmaceuticals 的持股比例 107.3%。Tower Research Capital LLC TRC 现在拥有该公司的 3,048 股股票，价值 34,000 美元，较上一季度增加了 1,578 股。Acadian Asset Management LLC 在第二季度收购了 Fennec Pharmaceuticals 的新头寸，价值约 49,000 美元。Jump Financial LLC 在第四季度收购了 Fennec Pharmaceuticals 的新头寸，价值约 158,000 美元。Rhumbline Advisers 在第二季度将其对 Fennec Pharmaceuticals 的持股比例增加了 44.7%。Rhumbline Advisers 现在拥有该公司的 29,110 股股票，价值 178,000 美元，较上一季度增加了 8,987 股。最后，BNP Paribas Financial Markets 在第一季度将其对 Fennec Pharmaceuticals 的持股比例增加了 67.7%。BNP Paribas Financial Markets 现在拥有该公司的 32,769 股股票，价值 364,000 美元，较上一季度增加了 13,223 股。机构投资者拥有该公司 55.51% 的股份。</p>
</div><h2>Fennec Pharmaceuticals Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Fennec Pharmaceuticals 公司简介（获取免费报告）</h2>
</div><p>Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.</p>
<div class="lb-trans"><p>Fennec Pharmaceuticals Inc 是一家生物制药公司，致力于开发用于治疗美国癌症的产品候选药物。其主要产品候选药物是硫代硫酸钠，已完成用于预防儿童顺铂诱导性听力损失或耳毒性的 III 期临床试验。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Fennec Pharmaceuticals</li>
<li>What Are Dividends? Buy the Best Dividend Stocks</li>
<li>Buy On Holdings Stock Before the Market Catches Its Second Wind?</li>
<li>How to Invest in Tech Stocks and Top Tech Stocks to Consider</li>
<li>3 High-Potential Stocks That Could Turn Into Multi-Baggers</li>
<li>What is a Bond Market Holiday? How to Invest and Trade</li>
<li>CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle</li>
</ul>
<div class="lb-trans"><h2>精选故事</h2>
<ul>
<li>我们喜欢的五只股票，比 Fennec Pharmaceuticals 更好</li>
<li>什么是股息？购买最佳股息股票</li>
<li>在市场抓住第二春之前购买 Holdings 股票</li>
<li>如何投资科技股，以及考虑的顶级科技股</li>
<li>3 只有潜力的股票可能成为多倍赚家</li>
<li>什么是债券市场假日？如何投资和交易</li>
<li>CEO 交换：星巴克因从 Chipotle 聘请新 CEO 而大涨 22%</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Secure this &#34;AI Fuel&#34; Stock Before the Billionaires Buy It All (From Behind the Markets)(Ad)</p>
<div class="lb-trans"><p>→ 在亿万富翁买光之前，先确保这支&#34;AI 燃料&#34;股票（来自市场背后）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTQ4" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9148&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Fennec Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资 1000 美元购买 Fennec Pharmaceuticals？</h2>
</div><p>Before you consider Fennec Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Fennec Pharmaceuticals 之前，您会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街顶级和表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 Fennec Pharmaceuticals 不在名单上。</p>
</div><p>While Fennec Pharmaceuticals currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Fennec Pharmaceuticals 目前在分析师中有&#34;买入&#34;评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Wedbush 重申对 Fennec Pharmaceuticals（NASDAQ:FENC）的跑赢大盘评级